HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Alain F. Carpentier Juan Carlos Chachques Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zakine, G. Articles by Chachques, J. C. Search for Related Content PubMed PubMed Citation Articles by Zakine, G. Articles by Chachques, J. C. Related Collections Cardiac - other

Ann Thorac Surg 2003;75:549-554
© 2003 The Society of Thoracic Surgeons

---

Original article: cardiovascular

Growth factors improve latissimus dorsi muscle vascularization and trophicity after cardiomyoplasty

^a Department of Cardiovascular Surgery, Broussais and Pompidou Hospitals, Paris, France

Accepted for publication August 22, 2002.

* Address reprint requests to Dr Chachques, Department of Cardiovascular Surgery, European Hospital Georges Pompidou, 20 Rue Leblanc, 75015 Paris, France.
e-mail: j.chachques{at}brs.ap-hop-paris.fr

BACKGROUND: Dynamic cardiomyoplasty consists of wrapping the electrostimulated latissimus dorsi muscle (LDM) around the failed heart. Partial ischemia followed by atrophy of the middle and distal part of the LDM were observed in 30% of clinical cases after LDM flap elevation from its origin. In the current study, we hypothesized that local administration of growth factors at the LDM/epicardial interface could improve muscle vascularization and trophicity.

METHODS: In 24 sheep, dynamic cardiomyoplasty was performed using the left LDM. A multiperforated catheter was positioned at the LDM/epicardial interface for a weekly administration, during a 1-month period, of the following factors: basic fibroblast growth factor (bFGF, n = 6), vascular endothelial growth factor (VEGF, n = 6), and regenerating agent (RGTA, n = 6). Six sheep injected with phosphate-buffered saline (used for dilution of the growth factors) were used as a control group. At 3 months, angiographic, histologic, and histomorphometric studies were performed.

RESULTS: Angiographic studies of the animals treated with growth factors demonstrated hypervascularization due to the development of new vessels. Histomorphometric and histologic studies showed a significant increase in the number of capillaries and arterioles (100 fields/muscle) in the groups treated with bFGF (443.0 ± 101.2, p < 0.01), RGTA (293.2 ± 29.3, p < 0.05), and VEGF (246.5 ± 45.9, p < 0.05), as compared with the control group (81.5 ± 11.4). A significantly lower atrophy score was observed in the groups treated with bFGF (1.4 ± 0.18, p < 0.05), RGTA (1.59 ± 0.17, p < 0.05), and VEGF (1.96 ± 0.14, NS), as compared with the control group (2.48 ± 0.16).

CONCLUSIONS: Local administration at the heart/muscle interface of growth factors increases muscle vascularization and avoids muscle atrophy in an experimental cardiomyoplasty model, both of which are advantageous to the contracting LDM. The local growth factors delivery system used in this study appears efficient, easy to implant, and manipulate and safe.

This article has been cited by other articles:

				V. Rouet, Y. Hamma-Kourbali, E. Petit, P. Panagopoulou, P. Katsoris, D. Barritault, J.-P. Caruelle, and J. Courty A Synthetic Glycosaminoglycan Mimetic Binds Vascular Endothelial Growth Factor and Modulates Angiogenesis J. Biol. Chem., September 23, 2005; 280(38): 32792 - 32800. [Abstract] [Full Text] [PDF]

				I. Barbosa, C. Morin, S. Garcia, A. Duchesnay, M. Oudghir, G. Jenniskens, H.-Q. Miao, S. Guimond, G. Carpentier, J. Cebrian, et al. A synthetic glycosaminoglycan mimetic (RGTA) modifies natural glycosaminoglycan species during myogenesis J. Cell Sci., January 1, 2005; 118(1): 253 - 264. [Abstract] [Full Text] [PDF]

				J.-S. Hulot, X. Jouven, J.-P. Empana, R. Frank, and G. Fontaine Natural History and Risk Stratification of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Circulation, October 5, 2004; 110(14): 1879 - 1884. [Abstract] [Full Text] [PDF]

				L. Barandon, T. Couffinhal, P. Dufourcq, P. Alzieu, D. Daret, C. Deville, and C. Duplaa Repair of Myocardial Infarction by Epicardial Deposition of Bone Marrow Cell-Coated Muscle Patch in a Murine Model Ann. Thorac. Surg., October 1, 2004; 78(4): 1409 - 1417. [Abstract] [Full Text] [PDF]

				J. C. Chachques, F. Duarte, B. Cattadori, A. Shafy, N. Lila, G. Chatellier, J.-N. Fabiani, and A. F. Carpentier Angiogenic growth factors and/or cellular therapy for myocardial regeneration: A comparative study J. Thorac. Cardiovasc. Surg., August 1, 2004; 128(2): 245 - 253. [Abstract] [Full Text] [PDF]

				J. C. Chachques, P. G. Argyriadis, G. Fontaine, J.-L. Hebert, R. A. Frank, N. D'Attellis, J.-N.o. Fabiani, and A. F. Carpentier Right ventricular cardiomyoplasty: 10-year follow-up Ann. Thorac. Surg., May 1, 2003; 75(5): 1464 - 1468. [Abstract] [Full Text] [PDF]